Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis

Clinical Nephrology

Volumn 69, Issue 6, 2008, Pages 433-435

  Doi, T ^a   Masaki, T ^a   Shiraki, N ^a   Kawai, T ^a   Yorioka, Noriaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Focal segmental glomer; Mizoribine; Nephrotic syndrome; Ulosclerosis

Indexed keywords

CYCLOSPORIN A; MIZORIBINE; PREDNISONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; MORNING DOSAGE; NEPHROTIC SYNDROME; RELAPSE; REMISSION;

EID: 44949205544     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69433     Document Type: Article

References (12)

1. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991; 36: 53-59.
2. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int. 1999; 56: 2220-2226.
3. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2002; 17: 2011-2013.
4. Kawasaki Y, Takano K, Isome M, Suzuki J, Suyama K, Kanno H, Fujiki T, Suzuki H, Hosoya M. Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol. 2007; 20: 52-56.
5. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S. Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol. 1999; 13: 113-116.
6. Segarra A, Vila J, Pou L, Majó J, Arbós A, Quiles T, Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002; 17: 655-662.
7. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, Shiiki H, Makino H, Sato H, Ishikawa I, Maeda K, Tomita K, Arakawa M, Ishida M, Sato M, Nagase M, Kashihara N, Yorioka N, Koike T, Saito T, Harada T, Mitarai T, Sugisaki T, Nagasawa T, Tomino Y, Nojima Y, Kobayashi Y, Sakai O. A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol. 2004; 8: 117-126.
8. Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, Teraoka S, Toma H, Ota K. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996; 28: 3643-3648.
9. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000; 274: 87-92.
10. Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol. 2006; 21: 962-966.
11. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005; 16: 1061-1068.
12. Yumura W, Uchida K, Kawashima A, Kobayashi H, Miwa N, Honda K, Nitta K, Nihei H. Evaluation of plasma concentration of mizoribine as an immunosupressive agent in lupus nephritis patients (in Japanese). Jin to Toseki (Kidney and Dial, Tokyo). 1999; 47: 705-708.